Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 6/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.68 |
| ▸ | MEN1 | O00255 | 4/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.62 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.62 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.55 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6887377 | 1.00 | POLB (0.68) | POLBKMT2AMEN1USP2NCOA1 | |
| SCHEMBL19736254 | 0.84 | POLB (0.88) | POLBKMT2AMEN1USP2NCOA1 | |
| SCHEMBL8712470 | 0.83 | ADAMTS5 (0.71) | AKR1B1PTPN1 | |
| SCHEMBL12008494 | 0.82 | PPARG (0.74) | POLBKMT2AMEN1NCOA3AKR1B1 | |
| SCHEMBL5219681 | 0.81 | ADAMTS5 (0.84) | AKR1B1PTPN1 | |
| SCHEMBL5219686 | 0.81 | ADAMTS5 (0.84) | AKR1B1PTPN1 | |
| SCHEMBL7145044 | 0.81 | AKR1B1 (0.67) | POLBKMT2AMEN1USP2NCOA1 | |
| SCHEMBL7145043 | 0.81 | AKR1B1 (0.67) | POLBKMT2AMEN1USP2NCOA1 | |
| SCHEMBL19736235 | 0.80 | POLB (1.00) | POLBKMT2AMEN1USP2NCOA1 | |
| SCHEMBL6886492 | 0.80 | MAPT (0.56) | POLBKMT2AMEN1PTPN1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673816-B1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | Esswein, Angelika (DE) | 2004-01-06 | — | — | US | disclosed |
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | ANGELIKA ESSWEIN, WOLFGANG SCHAEFER, AND KONRAD HONOLD | 2003-02-13 | — | — | US | disclosed |
| EP-1117655-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | Esswein, Angelika (DE) | 2001-07-25 | — | — | EP | disclosed |
| WO-2000018747-A1 | RHODANINE CARBOXYLIC ACID DERIVATIVES FOR THE TREATMENT AND PREVENTION OF METABOLIC BONE DISORDERS | ROCHE DIAGNOSTICS GMBH (DE) | 2000-04-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030032813-A1 | Rhodanine carboxylic acid derivatives for the treatment and prevention of metabolic bone disorders | NR1H4, NR1D1, NR1I2 | POLB 2514/4885KMT2A 1995/4885MEN1 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.